Brief: FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Kyntra Bio

24/09/2025 12:10

Sept 24 (Reuters) - FibroGen Inc FGEN.O:

FIBROGEN INITIATES PHASE 2 MONOTHERAPY TRIAL OF FG-3246, A FIRST-IN-CLASS CD46 TARGETING ADC, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

FIBROGEN INC - INTERIM ANALYSIS OF TRIAL EXPECTED IN 2H 2026

FIBROGEN INC - TOPLINE RESULTS OF FG-3246 IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH MCRPC ENZALUTAMIDE EXPECTED Q4 2025

Source text: ID:nGNXPK9K0

Further company coverage: FGEN.O

 ((Reuters.Briefs@thomsonreuters.com;))